NAN190 HBr

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 585403

CAS#: 115338-32-4 (HBr)

Description: NAN-190 is a mixed antagonist and partial agonist of the serotonin (5-HT) receptor subtype 5-HT1A. NAN-190 potentiates the circadian response to light and speeds re-entrainment to advanced light cycles. NAN-190 potentiates the impairment of retention produced by swim stress. NAN-190 is a possible antagonist for methamphetamine.

Chemical Structure

NAN190 HBr
CAS# 115338-32-4 (HBr)

Theoretical Analysis

MedKoo Cat#: 585403
Name: NAN190 HBr
CAS#: 115338-32-4 (HBr)
Chemical Formula: C23H28BrN3O3
Exact Mass: 0.00
Molecular Weight: 474.399
Elemental Analysis: C, 58.23; H, 5.95; Br, 16.84; N, 8.86; O, 10.12

Price and Availability

Size Price Availability Quantity
50mg USD 450 2 Weeks
100mg USD 750 2 Weeks
200mg USD 1250 2 Weeks
500mg USD 2450 2 Weeks
1g USD 3850 2 Weeks
Bulk inquiry

Related CAS #: 102392-05-2 (free base)   115338-32-4 (HBr),  

Synonym: NAN190 HBr; NAN190 hydrobromide; NAN-190; NAN190; NAN 190

IUPAC/Chemical Name: 2-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-1H-isoindole-1,3(2H)-dione, monohydrobromide


InChi Code: InChI=1S/C23H27N3O3.BrH/c1-29-21-11-5-4-10-20(21)25-16-14-24(15-17-25)12-6-7-13-26-22(27)18-8-2-3-9-19(18)23(26)28;/h2-5,8-11H,6-7,12-17H2,1H3;1H


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 474.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Fedotova IuO, Pivina SG, Akulova VK, Ordian NÉ. [Pecularities for action of combined administration of NAN-190 and ketanserine with low dose of 17β-estradiol on depression-like behavior in prenatally stressed ovariectomized rats]. Ross Fiziol Zh Im I M Sechenova. 2015 Jan;101(1):35-43. Russian. PMID: 25868324.

2: Fedotova IuO, Sapronov NS. [Co-administration of NAN-190 with low dose of testosterone propionate improves passive avoidance performance in rats with androgen deficiency]. Eksp Klin Farmakol. 2013;76(12):15-9. Russian. PMID: 24605422.

3: Fedotova IuO, Pivina SG, Ordian NÉ. [Analysis of 8-OH-DPAT and NAN-190 effects in young prenatally stressed rats under experimental estrogen deficiency conditions]. Eksp Klin Farmakol. 2012;75(7):11-4. Russian. PMID: 23025046.

4: Kowalski P, Jaśkowska J. An efficient synthesis of aripiprazole, buspirone and NAN-190 by the reductive alkylation of amines procedure. Arch Pharm (Weinheim). 2012 Jan;345(1):81-5. doi: 10.1002/ardp.201100112. Epub 2011 Oct 5. PMID: 22234973.

5: Fedotova YO, Ordyan NE. Effects of 8-OH-DPAT and NAN-190 on anxious- depressive-like behavior of female rats during the estrous cycle. Bull Exp Biol Med. 2010 Dec;150(2):165-7. English, Russian. doi: 10.1007/s10517-010-1094-x. PMID: 21246079.

6: Foong JP, Bornstein JC. 5-HT antagonists NAN-190 and SB 269970 block alpha2-adrenoceptors in the guinea pig. Neuroreport. 2009 Feb 18;20(3):325-30. doi: 10.1097/WNR.0b013e3283232caa. PMID: 19190523.

7: Kessler EJ, Sprouse J, Harrington ME. NAN-190 potentiates the circadian response to light and speeds re-entrainment to advanced light cycles. Neuroscience. 2008 Jul 17;154(4):1187-94. doi: 10.1016/j.neuroscience.2008.04.054. Epub 2008 May 6. PMID: 18538936; PMCID: PMC2637398.

8: Sterniczuk R, Stepkowski A, Jones M, Antle MC. Enhancement of photic shifts with the 5-HT1A mixed agonist/antagonist NAN-190: intra-suprachiasmatic nucleus pathway. Neuroscience. 2008 May 15;153(3):571-80. doi: 10.1016/j.neuroscience.2008.02.062. Epub 2008 Mar 6. PMID: 18406538.

9: Schneider AM, Simson PE. NAN-190 potentiates the impairment of retention produced by swim stress. Pharmacol Biochem Behav. 2007 May;87(1):73-80. doi: 10.1016/j.pbb.2007.04.002. Epub 2007 Apr 11. PMID: 17490739.

10: Sapronov NS, Fedotova YO, Losev NA. Combined administration of NAN-190 and 17beta-estradiol abolishes the amnesic effect of scopolamine in middle-aged ovariectomized rats. Bull Exp Biol Med. 2006 Jul;142(1):80-2. English, Russian. doi: 10.1007/s10517-006-0297-7. PMID: 17369909.

11: Paluchowska MH, Bugno R, Charakchieva-Minol S, Bojarski AJ, Tatarczyńska E, Chojnacka-Wójcik E. Conformational restriction in novel NAN-190 and MP3022 analogs and their 5-HT(1A) receptor activity. Arch Pharm (Weinheim). 2006 Sep;339(9):498-506. doi: 10.1002/ardp.200600009. PMID: 16941730.

12: Djavadian RL, Wielkopolska E, Turlejski K. Postnatal treatment with NAN-190 but not with 5-HT1A receptor agonists retards growth of the rat brain. Int J Dev Neurosci. 2005 Aug;23(5):485-93. doi: 10.1016/j.ijdevneu.2005.02.001. PMID: 16026684.

13: Ginawi OT, Al-Majed AA, Al-Suwailem AK. NAN-190, a possible specific antagonist for methamphetamine. Regul Toxicol Pharmacol. 2005 Mar;41(2):122-7. doi: 10.1016/j.yrtph.2004.10.005. Epub 2004 Dec 19. PMID: 15698535.

14: Wesołowska A, Borycz J, Paluchowska MH, Chojnacka-Wójcik E. Pharmacological analysis of the hypothermic effects of NAN-190 and its analogs, postsynaptic 5-HT1A receptor antagonists, in mice. Pol J Pharmacol. 2002 Jul-Aug;54(4):391-9. PMID: 12523493.

15: Paluchowska MH, Mokrosz MJ, Bojarski A, Wesołowska A, Borycz J, Charakchieva-Minol S, Chojnacka-Wójcik E. On the bioactive conformation of NAN-190 (1) and MP3022 (2), 5-HT(1A) receptor antagonists. J Med Chem. 1999 Dec 2;42(24):4952-60. doi: 10.1021/jm991045h. PMID: 10585205.

16: Cao BJ, Rodgers RJ. Influence of 5-HT1A receptor antagonism on plus-maze behaviour in mice. II. WAY 100635, SDZ 216-525 and NAN-190. Pharmacol Biochem Behav. 1997 Oct;58(2):593-603. doi: 10.1016/s0091-3057(97)00279-7. PMID: 9300624.

17: Belcheva I, Belcheva S, Petkov VV, Hadjiivanova C, Petkov VD. Behavorial responses to the 5-HT1A receptor antagonist NAN190 injected into rat CA1 hippocampal area. Gen Pharmacol. 1997 Mar;28(3):435-41. doi: 10.1016/s0306-3623(96)00185-1. PMID: 9068987.

18: Sharp T, Umbers V, Hjorth S. The role of 5-HT1A autoreceptors and alpha 1-adrenoceptors in the inhibition of 5-HT release--II NAN-190 and SDZ 216-525. Neuropharmacology. 1996 Jun;35(6):735-41. doi: 10.1016/0028-3908(96)84645-4. PMID: 8887982.

19: Dalpiaz A, Ferretti V, Gilli P, Bertolasi V. Stereochemistry of serotonin receptor ligands from crystallographic data. Crystal structures of NAN-190.HBr, 1-phenylbiguanide, MDL 72222 and mianserin.HCl and selectivity criteria towards 5-HT1, 5-HT2, and 5-HT3 receptor subtypes. Acta Crystallogr B. 1996 Jun 1;52 ( Pt 3):509-18. doi: 10.1107/s0108768195014765. PMID: 8767764.

20: Neckelmann D, Bjørkum AA, Bjorvatn B, Ursin R. Sleep and EEG power spectrum effects of the 5-HT1A antagonist NAN-190 alone and in combination with citalopram. Behav Brain Res. 1996 Feb;75(1-2):159-68. doi: 10.1016/0166-4328(96)00204-5. PMID: 8800653.